IE43449B1 - Process reducing the anticomplementary activity of gamma globulins - Google Patents
Process reducing the anticomplementary activity of gamma globulinsInfo
- Publication number
- IE43449B1 IE43449B1 IE2826/75A IE282675A IE43449B1 IE 43449 B1 IE43449 B1 IE 43449B1 IE 2826/75 A IE2826/75 A IE 2826/75A IE 282675 A IE282675 A IE 282675A IE 43449 B1 IE43449 B1 IE 43449B1
- Authority
- IE
- Ireland
- Prior art keywords
- gamma globulin
- aqueous solution
- gamma
- solution
- hydroxyethyl starch
- Prior art date
Links
- 108010074605 gamma-Globulins Proteins 0.000 title claims abstract description 51
- 238000000034 method Methods 0.000 title claims description 30
- 230000003171 anti-complementary effect Effects 0.000 title claims description 12
- 239000007864 aqueous solution Substances 0.000 claims abstract description 17
- 229920001612 Hydroxyethyl starch Polymers 0.000 claims abstract description 15
- 229940050526 hydroxyethylstarch Drugs 0.000 claims abstract description 15
- 239000000243 solution Substances 0.000 claims abstract description 13
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 9
- 210000004369 blood Anatomy 0.000 claims abstract description 9
- 239000008280 blood Substances 0.000 claims abstract description 9
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 6
- 239000010836 blood and blood product Substances 0.000 claims abstract description 5
- 229940125691 blood product Drugs 0.000 claims abstract description 5
- 238000005119 centrifugation Methods 0.000 claims description 7
- 230000000295 complement effect Effects 0.000 claims 1
- 239000002244 precipitate Substances 0.000 abstract description 16
- 239000000203 mixture Substances 0.000 abstract description 5
- 238000000926 separation method Methods 0.000 abstract description 5
- 239000006228 supernatant Substances 0.000 abstract description 5
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 238000010586 diagram Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 241000428352 Amma Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2500076A DE2500076C3 (de) | 1975-01-02 | 1975-01-02 | Verfahren zur Gewinnung von intravenös-verträglichen Gammaglobulinen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE43449L IE43449L (en) | 1976-07-02 |
| IE43449B1 true IE43449B1 (en) | 1981-02-25 |
Family
ID=5935911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE2826/75A IE43449B1 (en) | 1975-01-02 | 1975-12-30 | Process reducing the anticomplementary activity of gamma globulins |
Country Status (20)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2604759C2 (de) * | 1976-02-07 | 1983-06-01 | SCHURA Blutderivate GmbH & Co KG, 4150 Krefeld | Verfahren zur Gewinnung von iv-verträglichen Γglobulinen |
| JPS6016406B2 (ja) * | 1976-08-06 | 1985-04-25 | マイヤ−、ル−イス、コ−バル | 静脈内に投与可能なガンマ・グロブリンの製造法ならびにそれにより調製したガンマ・グロブリン |
| US4124576A (en) * | 1976-12-03 | 1978-11-07 | Coval M L | Method of producing intravenously injectable gamma globulin |
| GB1603244A (en) * | 1977-05-20 | 1981-11-18 | Max Planck Gesellschaft | Medicaments for the suppression of pathological processes |
| JPS5822085B2 (ja) * | 1977-07-19 | 1983-05-06 | 株式会社ミドリ十字 | 静注用ガンマ・グロブリン製剤 |
| AT359641B (de) * | 1978-09-19 | 1980-11-25 | Immuno Ag | Verfahren zur herstellung eines intravenoes ver- abreichbaren antikoerperhaeltigen immunglobulin- praeparates |
| EP0019403B1 (en) * | 1979-05-10 | 1985-07-31 | American Hospital Supply Corporation | Hydroxyalkyl-starch drug carrier |
| US4396608A (en) * | 1981-08-24 | 1983-08-02 | Cutter Laboratories | Intravenously injectable immune serum globulin |
| ATE19735T1 (de) * | 1982-02-08 | 1986-05-15 | Schweiz Serum & Impfinst | Intravenoes verabreichbares humanes immunglobulin und verfahren zu dessen herstellung. |
| US4482483A (en) * | 1983-04-06 | 1984-11-13 | Armour Pharmceutical Company | Composition of intravenous immune globulin |
| SE8302483L (sv) * | 1983-05-02 | 1984-11-03 | Pharmacia Ind | Forfarande vid rening av biologiskt aktiva substanser |
| US5945098A (en) * | 1990-02-01 | 1999-08-31 | Baxter International Inc. | Stable intravenously-administrable immune globulin preparation |
| DE19907257A1 (de) * | 1999-02-21 | 2000-09-14 | Bernd Horst Meier | Mittel zur Steuerung der Diffusion von Injektionslösungen |
| DE10040707A1 (de) * | 2000-08-17 | 2002-03-14 | Braun Melsungen Ag | Kolloidale Pharmakomodulation injizierter Arzneimittel |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| DK1954718T3 (en) | 2005-11-30 | 2014-12-15 | Abbvie Inc | Anti-A-globulomer antibodies antigenbindingsgrupper thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods for producing said antibodies, |
| KR20180058863A (ko) | 2005-11-30 | 2018-06-01 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| US8895004B2 (en) | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
| MX360403B (es) | 2010-04-15 | 2018-10-31 | Abbvie Inc | Proteinas de union a amiloide beta. |
| MX358739B (es) | 2010-08-14 | 2018-09-03 | Abbvie Inc Star | Proteinas de union a amiloide beta. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE348942B (enrdf_load_stackoverflow) * | 1970-06-02 | 1972-09-18 | Statens Bakteriologiska Labor | |
| DE2234069A1 (de) * | 1971-07-16 | 1973-02-08 | South African Inventions | Verfahren zur herstellung eines gereinigten gamma-globulins |
| ZA738779B (en) * | 1972-11-27 | 1974-10-30 | Baxter Laboratories Inc | Production of gamma globulin |
| JPS49101516A (enrdf_load_stackoverflow) * | 1973-01-13 | 1974-09-25 |
-
1975
- 1975-01-02 DE DE2500076A patent/DE2500076C3/de not_active Expired
- 1975-12-16 NL NLAANVRAGE7514627,A patent/NL179824C/xx not_active IP Right Cessation
- 1975-12-18 SE SE7514388A patent/SE437470B/xx not_active IP Right Cessation
- 1975-12-22 DK DK584375A patent/DK144679C/da active
- 1975-12-23 AT AT981675A patent/AT344883B/de active
- 1975-12-26 FR FR7539814A patent/FR2296429A1/fr active Granted
- 1975-12-27 JP JP15974275A patent/JPS5512001B2/ja not_active Expired
- 1975-12-29 DD DD190614A patent/DD121875A5/xx unknown
- 1975-12-29 GB GB53020/75A patent/GB1495159A/en not_active Expired
- 1975-12-30 ES ES443982A patent/ES443982A1/es not_active Expired
- 1975-12-30 IN IN2413/CAL/75A patent/IN143525B/en unknown
- 1975-12-30 IL IL48766A patent/IL48766A/xx unknown
- 1975-12-30 ZA ZA00758050A patent/ZA758050B/xx unknown
- 1975-12-30 AU AU87921/75A patent/AU505416B2/en not_active Expired
- 1975-12-30 CA CA242,734A patent/CA1058075A/en not_active Expired
- 1975-12-30 EG EG775/75A patent/EG11987A/xx active
- 1975-12-30 IE IE2826/75A patent/IE43449B1/en unknown
- 1975-12-30 BE BE6045314A patent/BE837211A/xx not_active IP Right Cessation
- 1975-12-31 SU SU7502306354A patent/SU576898A3/ru active
-
1976
- 1976-01-01 PL PL1976186289A patent/PL99599B1/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK144679B (da) | 1982-05-10 |
| GB1495159A (en) | 1977-12-14 |
| DK144679C (da) | 1982-10-11 |
| FR2296429A1 (fr) | 1976-07-30 |
| FR2296429B1 (enrdf_load_stackoverflow) | 1978-12-01 |
| BE837211A (fr) | 1976-06-30 |
| AU505416B2 (en) | 1979-11-22 |
| NL179824C (nl) | 1986-11-17 |
| IN143525B (enrdf_load_stackoverflow) | 1977-12-17 |
| ES443982A1 (es) | 1977-07-16 |
| PL99599B1 (pl) | 1978-07-31 |
| NL7514627A (nl) | 1976-07-06 |
| IE43449L (en) | 1976-07-02 |
| SE7514388L (sv) | 1976-07-05 |
| NL179824B (nl) | 1986-06-16 |
| DE2500076B2 (de) | 1979-02-22 |
| EG11987A (en) | 1981-12-31 |
| JPS5191321A (en) | 1976-08-10 |
| JPS5512001B2 (en) | 1980-03-29 |
| SE437470B (sv) | 1985-03-04 |
| ZA758050B (en) | 1976-12-29 |
| AT344883B (de) | 1978-08-10 |
| AU8792175A (en) | 1977-07-14 |
| CA1058075A (en) | 1979-07-10 |
| IL48766A0 (en) | 1976-02-29 |
| ATA981675A (de) | 1977-12-15 |
| DD121875A5 (enrdf_load_stackoverflow) | 1976-09-05 |
| DE2500076A1 (de) | 1976-07-08 |
| DK584375A (da) | 1976-07-03 |
| SU576898A3 (ru) | 1977-10-15 |
| IL48766A (en) | 1979-11-30 |
| DE2500076C3 (de) | 1982-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IE43449B1 (en) | Process reducing the anticomplementary activity of gamma globulins | |
| Andersson | The heterogeneity of bovine serum albumin | |
| US3992367A (en) | Process for the preparation of purified albumin by thermocoagulation and albumin obtained by said process | |
| Skeggs Jr et al. | The preparation and function of the hypertensin-converting enzyme | |
| Legaz et al. | Isolation and characterization of human factor VIII (antihemophilic factor) | |
| Weihing et al. | Acanthamoeba actin. Isolation and properties | |
| US4216205A (en) | Process of preparing a serum protein composition for intravenous application | |
| US5122373A (en) | Immunoglobulin-g-containing fraction | |
| US4278594A (en) | Process for separation and isolation of AHF, von Willebrand's ristocetin cofactor (VWF:RCF) and fibronectin from blood plasma | |
| US3808189A (en) | Isolation of gamma globulin preparations enriched in iga and igm using polyethylene glycol | |
| Tager | Concentration, partial purification, properties, and nature of staphylocoagulase | |
| US4670544A (en) | Process for the manufacture of the cold insoluble globulin and pharmaceutical preparation containing it | |
| US4027010A (en) | Antistaphylococcous human immunoglobulin and method of preparing same | |
| US4164495A (en) | Method of recovering immunoglobulin using a polyol and an alkanoic acid | |
| US4534906A (en) | Removal of impurities from human leukocyte interferon preparations | |
| US4476109A (en) | Method of preparing gamma globulin suitable for intravenous administration | |
| US4322403A (en) | Method for the preparation of an immune globulin solution suitable for intravenous use | |
| US4312949A (en) | Method for the preparation of a gamma globulin solution suitable for intravenous use | |
| USRE31268E (en) | Method of recovering immunoglobulin using a polyol and an alkanoic acid | |
| JPS62503036A (ja) | 静脈を介して投与されるガンマ−グロブリンの調製方法および該方法により得られたガンマ−グロブリン | |
| US4137222A (en) | Protein product, a process for preparation, and application of said product | |
| Dewey et al. | Studies on suramin (Antrypol: Bayer 205): 5. The combination of the drug with the plasma and other proteins | |
| US4478825A (en) | Warm ethanol method for preparation of low fibrinogen antihemophilic factor | |
| US2161861A (en) | Fractionation of proteinaceous fluids | |
| US4169829A (en) | Process for the preparation of purified albumin and albumin obtained by said process |